MarketPeel
Insider Trading Intelligence
Pricing
…
JS

Jean-pierre Sommadossi

AVIR
PRESIDENT, CEO, AND CHAIRMAN · ATEA PHARMACEUTICALS, INC. · CIK 0001296995
FILING MIX · LIFETIME54%/46%
BUYS
15
SELLS
13
TOTAL VALUE
$1.55M
COMPANIES
2
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
793,830
AVG SELL PX
$3.79
TRADE KIND
SHOWING 28 / 28
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 3 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Jean-pierre Sommadossi, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+80.00%-8.10%+1.46%-9.56%-10.49%—
14d5+100.00%-11.53%+1.58%-13.11%-14.45%—
30d5+60.00%-4.79%+3.96%-8.75%-8.71%—
60d5+100.00%-15.97%+3.38%-19.35%-20.34%—
90d5+100.00%-15.61%+5.05%-20.66%-20.27%—
180d5+100.00%-16.36%+5.41%-21.77%-23.23%—
1y5+100.00%-24.94%+18.31%-43.25%-44.65%—
2y5(3 pending)+0.00%+3.33%+43.55%-40.22%-40.22%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AVIR · 767,830 shares · as of Feb 3, 2026
01,481,2502,962,5004,443,7505,925,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 15 buys / 13 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
President, CEO, and Chairman
300,000——0Feb 3, 2026Feb 3, 2026 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASE
President, CEO, and Chairman
300,000$1.24$372.0K767,830Feb 3, 2026Feb 3, 2026 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
President, CEO, and Chairman
173,466——0Jan 31, 2026Feb 3, 2026 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
President, CEO, and Chairman
106,093$4.24$449.8K467,830Jan 31, 2026Feb 3, 2026 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASE
President, CEO, and Chairman
272,983——573,923Jan 31, 2026Feb 3, 2026 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
President, CEO, and Chairman
99,517——0Jan 31, 2026Feb 3, 2026 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASE
President, CEO, and Chairman
173,467——290,024Jan 31, 2025Feb 4, 2025 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
President, CEO, and Chairman
88,601$3.06$271.1K300,940Jan 31, 2025Feb 4, 2025 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
440,000——440,000Jan 31, 2025Feb 4, 2025 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
99,517——389,541Jan 31, 2025Feb 4, 2025 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
President, CEO, and Chairman
173,467——173,466Jan 31, 2025Feb 4, 2025 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
99,518——99,518Jan 31, 2025Feb 4, 2025 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,841$4.00$7.4K5,866,025Sep 19, 2024Sep 19, 2024 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
22,187$4.03$89.5K5,867,866Sep 18, 2024Sep 19, 2024 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
33,941$4.05$137.3K5,890,053Sep 17, 2024Sep 19, 2024 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
1,006$4.00$4.0K5,923,994Jun 5, 2024Jun 7, 2024 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE10b5-1
10b5-1 plan
56,910$3.85$218.8K116,557Feb 1, 2024Feb 2, 2024 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASE
President, CEO, and Chairman
173,467——173,467Jan 31, 2024Feb 2, 2024 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
448,000——448,000Jan 31, 2024Feb 2, 2024 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
President, CEO, and Chairman
173,467——346,933Jan 31, 2024Feb 2, 2024 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
728,600——728,600Jan 31, 2023Feb 2, 2023 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
520,400——520,400Jan 31, 2023Feb 2, 2023 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
378,033——378,033Jan 31, 2022Feb 2, 2022 ↗View →
KZR
KEZAR LIFE SCIENCES, INC.
PURCHASEGRANT
Stock grant
26,000——26,000Jun 28, 2021Jun 30, 2021 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASEGRANT
Stock grant
640,000——640,000Jan 29, 2021Feb 1, 2021 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASE
President, CEO, and Chairman
750,000——5,925,000Nov 3, 2020Nov 3, 2020 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
President, CEO, and Chairman
750,000——0Nov 3, 2020Nov 3, 2020 ↗View →
KZR
KEZAR LIFE SCIENCES, INC.
PURCHASEGRANT
Stock grant
8,896——8,896Jun 24, 2020Jun 26, 2020 ↗View →
Other insiders · AVIR
Loading peer insiders…
About this filer
CIK 0001296995
ROLE
President, CEO, and Chairman
PRIMARY
AVIR
COMPANIES
2
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001296995DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback